Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

You may be eligible if

• Subjects with documented Physician's diagnosis of COPD, and currently receiving maintenance therapy.
• Aged \>=40 years of age at inclusion.
• Using one of the maintenance therapies of interest for at least 3 months prior to inclusion on the study.
• Males or females.
• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in the protocol.
• Drug/alcohol abuse: Subjects with a known or suspected alcohol or drug abuse history at screening (Visit 0) that in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement.
• Investigational product: Subjects who have received an investigational drug and/or medical device within 30 days of entry into this study (Screening/Visit 1), or within five half-lives of the investigational drug, whichever is longer.
• Investigational product: Subjects who have been trained during participation in any device study in the 6 months prior to entry into this study.